This is a Phase 2, open-label, multicenter,study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant - Page 1 of 5 - protein) combine with IMM27M(Anti-CTLA-4 Humanized monoclonal antibody) in patients with advanced hepatocellular carcinoma who not have received the treatment for aHCC in past
Age greater than or equal to 18 years old and ≤ 75 years old at the same time of signing the informed consent.
Histologically or cytologically confirmed for HCC
Eastern Cooperative Oncology Group (ECOG) 0 to 1.
Adequate organ function as defined in protocol.
History of other malignancy within the past 5 years with exceptions.
Systemic chemotherapy was administered within 4 weeks prior to the first administration.
Activated symptomatic brain metastases and leptomeningeal disease.
History of hepatic encephalopathy disease in past 12 months.